- Home
- LGL vs PULM Comparison
LGL vs PULM Comparison
Compare LGL & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGL
- PULM
- Stock Information
- Founded
- LGL 1917
- PULM 2003
- Country
- LGL United States
- PULM United States
- Employees
- LGL N/A
- PULM N/A
- Industry
- LGL Industrial Machinery/Components
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- LGL Technology
- PULM Health Care
- Exchange
- LGL Nasdaq
- PULM Nasdaq
- Market Cap
- LGL 35.6M
- PULM 33.2M
- IPO Year
- LGL N/A
- PULM N/A
- Fundamental
- Price
- LGL $6.87
- PULM $6.94
- Analyst Decision
- LGL
- PULM
- Analyst Count
- LGL 0
- PULM 0
- Target Price
- LGL N/A
- PULM N/A
- AVG Volume (30 Days)
- LGL 38.9K
- PULM 62.8K
- Earning Date
- LGL 08-12-2025
- PULM 08-12-2025
- Dividend Yield
- LGL N/A
- PULM N/A
- EPS Growth
- LGL 204.51
- PULM N/A
- EPS
- LGL 0.08
- PULM N/A
- Revenue
- LGL $4,322,000.00
- PULM $1,921,000.00
- Revenue This Year
- LGL N/A
- PULM N/A
- Revenue Next Year
- LGL N/A
- PULM $134.88
- P/E Ratio
- LGL $95.56
- PULM N/A
- Revenue Growth
- LGL 20.66
- PULM N/A
- 52 Week Low
- LGL $5.03
- PULM $1.78
- 52 Week High
- LGL $9.74
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- LGL 60.84
- PULM 42.62
- Support Level
- LGL $5.88
- PULM $6.36
- Resistance Level
- LGL $9.74
- PULM $7.99
- Average True Range (ATR)
- LGL 0.87
- PULM 0.90
- MACD
- LGL 0.05
- PULM -0.24
- Stochastic Oscillator
- LGL 34.97
- PULM 50.16
About LGL LGL Group Inc. (The)
LGL Group Inc is a holding company engaged in services, merchant investment and manufacturing business activities. The company has two reportable segments; Electronic Instruments and Merchant Investment. The Electronic Instruments segment, which generates key revenue, is focused on designing and manufacturing high-performance Frequency and Time reference standards that form the basis for timing and synchronization in various applications including satellite communication, time transfer systems, network synchronization, electricity distribution, and metrology. The Merchant Investment segment comprises various investment vehicles in which the company invests its capital.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).